Pfizer Limited - Asset Resilience Ratio
Pfizer Limited (PFIZER) has an Asset Resilience Ratio of 60.66% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PFIZER working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2026)
This chart shows how Pfizer Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PFIZER total assets.
Liquid Assets Composition Over Time
This chart breaks down Pfizer Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Pfizer Limited (PFIZER) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs29.86 Billion | 60.66% |
| Total Liquid Assets | Rs29.86 Billion | 60.66% |
Asset Resilience Insights
- Very High Liquidity: Pfizer Limited maintains exceptional liquid asset reserves at 60.66% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pfizer Limited Industry Peers by Asset Resilience Ratio
Compare Pfizer Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357 |
Drug Manufacturers - General | 9.91% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Annual Asset Resilience Ratio for Pfizer Limited (2005–2026)
The table below shows the annual Asset Resilience Ratio data for Pfizer Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 60.66% | Rs29.86 Billion ≈ $322.90 Million |
Rs49.22 Billion ≈ $532.28 Million |
+4.04pp |
| 2025-03-31 | 56.62% | Rs27.81 Billion ≈ $300.72 Million |
Rs49.11 Billion ≈ $531.12 Million |
+8.80pp |
| 2024-03-31 | 47.82% | Rs20.22 Billion ≈ $218.70 Million |
Rs42.29 Billion ≈ $457.33 Million |
+2.04pp |
| 2023-03-31 | 45.79% | Rs18.32 Billion ≈ $198.10 Million |
Rs40.01 Billion ≈ $432.66 Million |
+5.25pp |
| 2022-03-31 | 40.54% | Rs15.81 Billion ≈ $171.01 Million |
Rs39.01 Billion ≈ $421.83 Million |
+8.66pp |
| 2021-03-31 | 31.88% | Rs10.41 Billion ≈ $112.59 Million |
Rs32.66 Billion ≈ $353.19 Million |
-17.70pp |
| 2020-03-31 | 49.58% | Rs21.84 Billion ≈ $236.21 Million |
Rs44.05 Billion ≈ $476.43 Million |
+2.02pp |
| 2019-03-31 | 47.55% | Rs18.74 Billion ≈ $202.63 Million |
Rs39.40 Billion ≈ $426.09 Million |
+0.81pp |
| 2018-03-31 | 46.75% | Rs17.25 Billion ≈ $186.56 Million |
Rs36.90 Billion ≈ $399.06 Million |
+1.28pp |
| 2017-03-31 | 45.47% | Rs14.87 Billion ≈ $160.81 Million |
Rs32.71 Billion ≈ $353.71 Million |
+45.32pp |
| 2016-03-31 | 0.15% | Rs43.26 Million ≈ $467.81K |
Rs29.14 Billion ≈ $315.11 Million |
+0.15pp |
| 2012-03-31 | 0.00% | Rs500.00K ≈ $5.41K |
Rs15.76 Billion ≈ $170.49 Million |
-39.68pp |
| 2011-03-31 | 39.68% | Rs5.50 Billion ≈ $59.49 Million |
Rs13.86 Billion ≈ $149.92 Million |
+8.76pp |
| 2010-03-31 | 30.92% | Rs3.72 Billion ≈ $40.24 Million |
Rs12.03 Billion ≈ $130.14 Million |
+8.33pp |
| 2009-03-31 | 22.59% | Rs2.48 Billion ≈ $26.82 Million |
Rs10.98 Billion ≈ $118.71 Million |
-30.54pp |
| 2008-03-31 | 53.13% | Rs4.61 Billion ≈ $49.85 Million |
Rs8.67 Billion ≈ $93.81 Million |
+42.82pp |
| 2007-03-31 | 10.31% | Rs666.73 Million ≈ $7.21 Million |
Rs6.47 Billion ≈ $69.92 Million |
-1.16pp |
| 2006-03-31 | 11.47% | Rs660.82 Million ≈ $7.15 Million |
Rs5.76 Billion ≈ $62.30 Million |
-1.92pp |
| 2005-03-31 | 13.39% | Rs699.09 Million ≈ $7.56 Million |
Rs5.22 Billion ≈ $56.47 Million |
-- |
About Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers therapy area and products, such as vaccines, injectables and anti-infectives, inflammation and immunology, and internal medicine for cardiovascular care, oncology, respiratory, multivitamins and multimineral, neuroscience, women's health, gastroenterolog… Read more